Skip to Content

Tumor-Killing Nanoparticles

A new class of imaging particles seeks out cancers’ blood vessels.
March 1, 2007

A new class of nanoparticles that accumulate inside tumors could one day improve imaging quality and cancer treatment by delivering image-­enhancing agents or cancer drugs directly to tumor sites. A team led by Erkki Ruoslahti, a professor at the Burnham Institute for Medical Research in La Jolla, CA, coated iron oxide nanoparticles with a peptide that is attracted to protein clots in tumor blood vessels. When injected into mice with breast cancer, the nanoparticles sought out the tumors and bound to their blood-vessel walls. For reasons the researchers do not yet understand, the particles also induced more clotting, which attracted more particles, enhancing their effectiveness and potentially choking off a tumor’s lifeblood. The team is working to ensure that the particles won’t build up in normal tissues.

Fluorescent peptides attached to iron oxide particles glow bright green in a tumor (top left) and in the liver in these images of mice.

Keep Reading

Most Popular

DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.

“This is a profound moment in the history of technology,” says Mustafa Suleyman.

What to know about this autumn’s covid vaccines

New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.

Human-plus-AI solutions mitigate security threats

With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure

Next slide, please: A brief history of the corporate presentation

From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.